Malathion
As of the edition of 20 October 2026, Malathion is a small molecule: marketed, first approved in 1982 (US); US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Ovide
- First approved
- 2 August 1982 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Taro Pharmaceutical Industries
- Registered trials
- 5, 0 stopped early
- Disease areas
- Infections; Skin and connective tissue
US protection
US protection ends in 2027.
The last listed US drug-substance patent ends in 2027. The application that gives this date is held by Taro Pharmaceutical Industries.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 3 | 4 | 4 | 0 | 0 |
| All trials | 5 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Purdue Frederick | Earlier holder | 1982 to now |
| Taro Pharmaceutical Industries | Acquired holder | 2017 to now |